Manuscript no. HAEMATOL/2011/043471 entitled "Association between SNPgenotype and chronic lymphocytic leukemia outcome in a randomized chemotherapy trial"

Authors: Rachel Wade, Maria Chiara Di Bernardo, Sue Richards, Davide Rossi, Dalemari Crowther-Swanepoel, Gianluca Gaidano, David G. Oscier, Daniel Catovsky and Richard S. Houlston

Information about the contributions of each person named as having participated in the study

Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
Richard S. Houlston, Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, SM2 5NG. UK, E-mail: richard.houlston@icr.ac.uk

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the **conception of the study**: Richard S. Houlston, Daniel Catovsky

3) Design & Methods. The following authors were responsible for specific :

• Daniel Catovsky, David G. Oscier, Davide Rossi and Gianluca Gaidano were responsible for overseeing patient recruitment.

• Dalemari Crowther-Swanepoel was responsible for performing replication genotyping.

4) **Results**. The following authors were responsible for specific portions of the results, including figures and tables:

• Rachel Wade, Maria Chiara Di Bernardo and Sue Richards were responsible for performing statistical analysis.

• Rachel Wade was responsible for Figure 2, Table 1, Supplementary Tables 1 and 3.

• Maria Chiara Di Bernardo was responsible for Table 2, Figures 1 and 3, Supplementary Tables 2 and 4.

5) Writing the manuscript. The following authors were responsible for writing the manuscript:

• Richard S. Houlston was responsible for writing the manuscript.

• Maria Chiara Di Bernardo, Rachel Wade, Davide Rossi and Daniel Catovsky were responsible for substantial contributions to the manuscript.

6) Contributors Listed in Acknowledgments:

The authors would like to thank all patients and clinicians participating in the LRF CLL-4 trial. This work was primarily supported by a grant from Leukaemia Research and the MRC (G8223452). Additional funding was provided by the Arbib Foundation and Cancer Research UK.